{"category": "ham", "to_address": "ip-health@lists.essential.org", "from_address": "Mike Palmedo <mpalmedo@wcl.american.edu>", "subject": "[Ip-health] 12 Years Data Exclusivity in US Compromise Legislation for Biogenerics/Biosimilars", "body": "This is from compromise language for a bill to permit the approval of\ngeneric biologics, or biosimilars.  The bill includes 12 years of data\nexclusivity.  Some clinical trials would be required for generic\napproval, though the FDA could waive the requirement on a case-by-case\nbasis.\n\nFull text of the legislation, which would give biologics 12 years of\ndata exclusivity:\nhttp://www.biologicdrugreport.com/News/Docs/compromise-0607.pdf\n\n[snip]\n\n(7) EXCLUSIVITY FOR REFERENCE PRODUCT -\n\n(A)  EFFECTIVE DATE OF BIOSIMILAR APPLICATION APPROVAL - Approval of an\napplication under this subsection may not be made effective by the\nSecretary until the date that is 12 years after the date on which the\nreference product was first licensed under subsection (a).\n\n[snip]\n\n--\nMike Palmedo\nResearch Coordinator\nProgram on Information Justice and Intellectual Property\nAmerican University, Washington College of Law\n4910 Massachutsetts Ave., NW Washington, DC 20016\nT - 202-274-4442 | F 202-274-0659\nmpalmedo@wcl.american.edu\n\n\n_______________________________________________\nIp-health mailing list\nIp-health@lists.essential.org\nhttp://lists.essential.org/mailman/listinfo/ip-health\n\n"}